Immune cell engagers therapy(AI Proteins)

N/A

Report date: 2025/01/02 17:37:50

Base Information

Drug NameImmune cell engagers therapy(AI Proteins)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionT lymphocyte replacementsLow affinity immunoglobulin gamma Fc region receptor III-A modulatorsAnti-Leukocyte immunoglobulin-like receptor subfamily B member 4

TargetsLow affinity immunoglobulin gamma Fc region receptor III-ALeukocyte immunoglobulin-like receptor subfamily B member 4

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAI Proteins Inc

China Registration ClassN/A

Develop Information

Active CompaniesAI Proteins Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A